Chroman-3-amides as potent Rho kinase inhibitors - PubMed (original) (raw)
. 2008 Dec 15;18(24):6406-9.
doi: 10.1016/j.bmcl.2008.10.080. Epub 2008 Oct 22.
Thomas D Bannister, Amiee Weiser, Evelyn Griffin, Li Lin, Claudia Ruiz, Michael D Cameron, Stephan Schürer, Derek Duckett, Thomas Schröter, Philip LoGrasso, Yangbo Feng
Affiliations
- PMID: 18990570
- DOI: 10.1016/j.bmcl.2008.10.080
Chroman-3-amides as potent Rho kinase inhibitors
Yen Ting Chen et al. Bioorg Med Chem Lett. 2008.
Abstract
Inhibition of Rho kinase (ROCK) is an attractive strategy for the treatment of diseases such as hypertension, glaucoma, and cancer. Here we report chroman-3-amides as highly potent ROCK inhibitors with sufficient kinase selectivity, excellent cell activity, good microsomal stability, and desirable pharmacokinetic properties for study as potential therapeutic agents.
Similar articles
- Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
Sessions EH, Yin Y, Bannister TD, Weiser A, Griffin E, Pocas J, Cameron MD, Ruiz C, Lin L, Schürer SC, Schröter T, LoGrasso P, Feng Y. Sessions EH, et al. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6390-3. doi: 10.1016/j.bmcl.2008.10.095. Epub 2008 Oct 25. Bioorg Med Chem Lett. 2008. PMID: 18996009 - Kinase array design, back to front: biaryl amides.
Baldwin I, Bamborough P, Haslam CG, Hunjan SS, Longstaff T, Mooney CJ, Patel S, Quinn J, Somers DO. Baldwin I, et al. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5285-9. doi: 10.1016/j.bmcl.2008.08.051. Epub 2008 Aug 22. Bioorg Med Chem Lett. 2008. PMID: 18789685 - Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
Yin Y, Lin L, Ruiz C, Cameron MD, Pocas J, Grant W, Schröter T, Chen W, Duckett D, Schürer S, Lograsso P, Feng Y. Yin Y, et al. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6686-90. doi: 10.1016/j.bmcl.2009.09.115. Epub 2009 Oct 3. Bioorg Med Chem Lett. 2009. PMID: 19837589 - Vascular rho kinases and their potential therapeutic applications.
Budzyn K, Sobey CG. Budzyn K, et al. Curr Opin Drug Discov Devel. 2007 Sep;10(5):590-6. Curr Opin Drug Discov Devel. 2007. PMID: 17786858 Review. - Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.
Feng Y, LoGrasso PV, Defert O, Li R. Feng Y, et al. J Med Chem. 2016 Mar 24;59(6):2269-300. doi: 10.1021/acs.jmedchem.5b00683. Epub 2015 Oct 30. J Med Chem. 2016. PMID: 26486225 Review.
Cited by
- Computer-aided discovery of phenylpyrazole based amides as potent S6K1 inhibitors.
Yin Y, Sun Y, Zhao L, Pan J, Feng Y. Yin Y, et al. RSC Med Chem. 2020 Apr 30;11(5):583-590. doi: 10.1039/c9md00537d. eCollection 2020 May 1. RSC Med Chem. 2020. PMID: 33479660 Free PMC article. - ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway.
Moskal N, Riccio V, Bashkurov M, Taddese R, Datti A, Lewis PN, Angus McQuibban G. Moskal N, et al. Nat Commun. 2020 Jan 3;11(1):88. doi: 10.1038/s41467-019-13781-3. Nat Commun. 2020. PMID: 31900402 Free PMC article. - Mutant huntingtin enhances activation of dendritic Kv4 K+ channels in striatal spiny projection neurons.
Carrillo-Reid L, Day M, Xie Z, Melendez AE, Kondapalli J, Plotkin JL, Wokosin DL, Chen Y, Kress GJ, Kaplitt M, Ilijic E, Guzman JN, Chan CS, Surmeier DJ. Carrillo-Reid L, et al. Elife. 2019 Apr 24;8:e40818. doi: 10.7554/eLife.40818. Elife. 2019. PMID: 31017573 Free PMC article. - Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents.
Yao Y, Li R, Liu X, Yang F, Yang Y, Li X, Shi X, Yuan T, Fang L, Du G, Jiao X, Xie P. Yao Y, et al. Molecules. 2017 Oct 19;22(10):1766. doi: 10.3390/molecules22101766. Molecules. 2017. PMID: 29048389 Free PMC article. - In silico prediction of ROCK II inhibitors by different classification approaches.
Cai C, Wu Q, Luo Y, Ma H, Shen J, Zhang Y, Yang L, Chen Y, Wen Z, Wang Q. Cai C, et al. Mol Divers. 2017 Nov;21(4):791-807. doi: 10.1007/s11030-017-9772-5. Epub 2017 Aug 2. Mol Divers. 2017. PMID: 28770474
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical